ストックスクリーナーアプリを入手
3.47
1.76%
0.06
アフターアワーズ：
3.31
-0.16
-4.61%
前日終値:
$3.41
開ける：
$3.38
24時間の取引高:
28,990
Relative Volume:
0.15
時価総額：
$5.06M
収益：
$12.99M
当期純損益:
$-23.72M
株価収益率:
-0.0357
EPS:
-97.2514
ネットキャッシュフロー:
$-23.28M
1週間 パフォーマンス:
+3.89%
1か月 パフォーマンス:
-22.89%
6か月 パフォーマンス:
-75.32%
1年 パフォーマンス:
-98.53%
1日の値動き範囲:
$3.3161
$3.5832
1週間の範囲:
$3.20
$3.6699
52週間の値動き範囲:
$3.0101
$399.60
Aptevo Therapeutics Inc Stock (APVO) Company Profile
APVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
3.47 | 5.06M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2018-11-05 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-10-05 | 再開されました | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc (APVO) 最新ニュース
Roth Capital Brokers Decrease Earnings Estimates for APVO - Defense World
FY2029 Earnings Estimate for APVO Issued By Roth Capital - Defense World
Aptevo Therapeutics files $100M mixed securities shelf - MSN
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Exclusive: Aptevo's Revolutionary Cancer Treatment Achieves 100% Remission RateCEO Interview Alert - StockTitan
Aptevo Therapeutics (NASDAQ:APVO) Stock Quotes, Forecast and News Summary - Benzinga
Aptevo Therapeutics Inc. (APVO) reports earnings - Quartz
Aptevo Therapeutics Inc. SEC 10-K Report - TradingView
Aptevo Therapeutics reports FY24 EPS ($87.38) vs. ($2,316.83) last year - TipRanks
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update - StockTitan
APVO stock plunges to 52-week low at $3.62 amid steep annual decline - MSN
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025 - ACCESS Newswire
APVO stock plunges to 52-week low at $3.62 amid steep annual decline By Investing.com - Investing.com South Africa
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding - ACCESS Newswire
Aptevo Therapeutics Collects $750,000 Working Capital Escrow From Medexus Related to IXINITY(R) Sale - ACCESS Newswire
Aptevo Therapeutics Showcases Promising Oncology Drug Pipeline - TipRanks
TG Therapeutics (NASDAQ:TGTX) vs. Aptevo Therapeutics (NASDAQ:APVO) Head-To-Head Review - Defense World
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial - ACCESS Newswire
Aptevo Therapeutics Regains Compliance With Nasdaq Listing Requirements - ACCESS Newswire
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Decline in Short Interest - Defense World
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan - ACCESS Newswire
Aptevo Therapeutics Announces First Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial - ACCESS Newswire
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation - ACCESS Newswire
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting - ACCESS Newswire
Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial - ACCESS Newswire
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies - ACCESS Newswire
Aptevo Therapeutics Doses First Patient in IXINITY Clinical Trial for Potential Pediatric Label Expansion - ACCESS Newswire
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan - ACCESS Newswire
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - ACCESS Newswire
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update - ACCESS Newswire
Aptevo's Senior Director to Present ADAPTIR Platform at Major Biotech Conference PepTalk 2025 - StockTitan
Trend Tracker for (APVO) - Stock Traders Daily
Are Medical Stocks Lagging Aptevo Therapeutics (APVO) This Year? - Yahoo Finance
Aptevo Therapeutics Stock Draws Retail Attention After Leukemia Trial Data: Retail Extremely Bullish - MSN
APVO stock touches 52-week low at $5.1 amid sharp annual decline - Investing.com Australia
Aptevo Therapeutics Inc. Announces 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline Aml Trial - Marketscreener.com
Aptevo reports full remission in AML trial - Investing.com India
Aptevo reports full remission in AML trial By Investing.com - Investing.com UK
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial - AccessWire
Aptevo's AML Drug Trial Hits 100% Remission Rate, Complete Cancer Cell Elimination in Phase 1b Study - StockTitan
(APVO) On The My Stocks Page - Stock Traders Daily
Aptevo Therapeutics executes reverse stock split - Investing.com India
Aptevo Therapeutics executes reverse stock split By Investing.com - Investing.com Australia
Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects - AccessWire
Aptevo's Novel Prostate Cancer Therapy Shows Promise in Preclinical Studies, Targets $24B Market - StockTitan
Sweden’s Alligator Makes Cuts To Avoid Extinction - News & Insights
Alligator Bioscience completes a rights issue of SEK 280 million - Marketscreener.com
Alligator Bioscience to make a rights issue of units of SEK 199 million - Marketscreener.com
Aptevo Therapeutics announces 1-for-37 reverse stock split By Investing.com - Investing.com Nigeria
Stock Market Movers Today • Top Gainers & Losers - Benzinga
What's Going On With Aptevo Therapeutics Shares Friday? - Benzinga
Aptevo Therapeutics Inc (APVO) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):